<DOC>
	<DOC>NCT01698164</DOC>
	<brief_summary>This study is to evaluate the benefit/risk of hormone replacement treatment among early menopausal women in China. This is a multi-centre, random, prospective study.</brief_summary>
	<brief_title>Multi-centre Clinical Trial on Hormone Replacement Treatment in China</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>going through amenorrhea above 6 months and within 5 years, aged 40 to 60 years, going though postmenopausal symptoms, serum E2 concentration &lt;30pg/ml, serum FSH concentration &gt;40IU/L. uterine fibroid diameter≥5cm, history of diabetes or hypertension, history of thromboembolism, severe endometriosis, epilepsy, asthma, hyperprolactinemia, first degree relative had a history of breast cancer, being in severe or unstable condition of somatic diseases, receiving HRT in the past 3 month, drug or alcohol abuse in the past 3 month, endometrial thickness ≥0.5cm after withdrawal bleeding, being allergic to the medicine, participating in other clinical trials within 1 month ago.</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>lipid profiles</keyword>
	<keyword>coronary heart disease</keyword>
	<keyword>menopausal syndrome</keyword>
	<keyword>MMSE</keyword>
	<keyword>MENQOL</keyword>
	<keyword>HAD</keyword>
</DOC>